Medtronic generated third quarter fiscal 2026 revenue of 9017000000, up 8.7% reported and 6.0% organic, with GAAP net income of 1143000000 and diluted EPS of 0.89. Growth was led by double-digit Cardiovascular performance and strong Diabetes expansion, while operating margins remained solid.

Medtronic delivered a solid performance in Q2 2026, exceeding revenue and EPS expectations. The company saw strong growth in its Cardiac Ablation Solutions and Cardiovascular segments, leading to an upward revision of its full-year guidance.

Medtronic reported strong Q1 FY26 results with $8.58B in revenue and consistent organic growth across cardiovascular and diabetes segments. GAAP EPS rose to $0.81 while non-GAAP EPS reached $1.26, prompting an upward revision of full-year earnings guidance.

Medtronic delivered a robust Q4 FY25 performance with nearly $9 billion in revenue and strong growth in key franchises such as Cardiac Ablation and Diabetes. The company also announced a strategic plan to spin off its Diabetes business.

Medtronic reported revenue growth of 2.5% YoY, with strong performance in Pulsed Field Ablation, Neuromodulation, and Diabetes. Adjusted EPS grew 7% YoY, driven by operating margin expansion. The company reiterated its full-year guidance.

Medtronic reported a strong second quarter in fiscal year 2025, with revenue of $8.4 billion, a 5.3% increase as reported and 5.0% organic. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS reached $1.26. The company has raised its full-year guidance for both organic revenue growth and EPS.

Medtronic reported Q1 worldwide revenue of $7.915 billion, an increase of 2.8% as reported and 5.3% on an organic basis. GAAP diluted earnings per share (EPS) were $0.80; non-GAAP diluted EPS of $1.23. The company raised its FY25 organic revenue growth guidance to 4.5% to 5% and diluted non-GAAP EPS guidance to the new range of $5.42 to $5.50.

Medtronic reported Q4 worldwide revenue of $8.589 billion, a 0.5% increase as reported and a 5.4% increase on an organic basis. GAAP diluted EPS was $0.49, while non-GAAP diluted EPS was $1.46. The company's organic revenue results reflect broad-based growth across the company, with mid-single digit or higher organic revenue growth in all four segments.

Medtronic reported a 4.7% increase in revenue to $8.1 billion, with organic revenue growth of 4.6%. GAAP EPS was $0.99, and non-GAAP EPS was $1.30. The company raised its full-year organic revenue growth and EPS guidance.

Medtronic reported a solid Q2 2024 with revenue of $8.0 billion, a 5.3% increase as reported and 5.0% organically. GAAP EPS was $0.68, and non-GAAP EPS was $1.25. The company raised its FY24 organic revenue growth and EPS guidance.

Medtronic reported a solid start to fiscal year 2024, with revenue of $7.7 billion, a 4.5% increase as reported and 6.0% organic. GAAP EPS was $0.59, a 16% decrease, while non-GAAP EPS was $1.20, a 6% increase. The company has raised its FY24 organic revenue growth and EPS guidance.

Medtronic reported a strong finish to fiscal year 2023, with Q4 revenue of $8.5 billion, a 5.6% increase as reported and organic. GAAP diluted EPS was $0.88, a 20% decrease, while non-GAAP diluted EPS was $1.57, a 3% increase. The company issued FY24 guidance, projecting organic revenue growth in the range of 4.0% to 4.5% and non-GAAP EPS in the range of $5.00 to $5.10.

Medtronic's Q3 2023 revenue reached $7.7 billion, remaining flat as reported but increasing by 4.1% organically, surpassing expectations. GAAP diluted EPS was $0.92, a 16% decrease, while non-GAAP diluted EPS was $1.30, a 4% decrease, also exceeding expectations. The company has raised its FY23 organic revenue growth and EPS outlook.

Medtronic reported a 3% decrease in revenue, totaling $7.6 billion, but experienced a 2% increase on an organic basis. GAAP diluted EPS decreased by 67% to $0.32, while non-GAAP diluted EPS decreased by 2% to $1.30. The company has updated its guidance and anticipates organic revenue growth to accelerate in the second half of the fiscal year.

Medtronic's Q1 2023 revenue reached $7.371 billion, a decrease of 8% as reported and 4% organically. GAAP diluted EPS increased by 25% to $0.70, while non-GAAP diluted EPS decreased by 17% to $1.13. The company reiterated its FY23 revenue and EPS guidance.

Medtronic reported a 1% decrease in Q4 revenue to $8.1 billion, but a 1% increase on an organic basis. GAAP diluted EPS increased by 10% to $1.10, while non-GAAP diluted EPS increased by 2% to $1.52. The company issued FY23 guidance, expecting organic revenue growth of 4% to 5% and non-GAAP EPS in the range of $5.53 to $5.65.

Medtronic reported flat revenue year-over-year at $7.8 billion, with 2% organic growth. GAAP diluted EPS grew 17% to $1.10, while non-GAAP diluted EPS increased 6% to $1.37. The company issued Q4 revenue and EPS guidance, expecting healthcare procedures to reaccelerate post-Omicron.

Medtronic reported a 3% increase in revenue to $7.8 billion, with organic revenue growth of 2%. GAAP diluted EPS increased by 169% to $0.97, while non-GAAP diluted EPS increased by 29% to $1.32. The company is reiterating its full year EPS guidance.

Medtronic reported a strong start to fiscal year 2022, with Q1 revenue of $8.0 billion, a 23% increase as reported and 19% on an organic basis. GAAP diluted EPS was $0.56, while non-GAAP diluted EPS was $1.41. The company reiterated its FY22 revenue guidance and raised the lower end of its EPS guidance.

Medtronic reported a strong end to fiscal year 2021, with fourth quarter revenue of $8.188 billion, a 37% increase as reported and 32% organically. GAAP diluted EPS was $1.00, and non-GAAP diluted EPS was $1.50. The company announced a 9% dividend increase and issued FY22 guidance.

Medtronic reported a Q3 revenue of $7.775 billion, a 0.8% increase as reported, but a 1.0% decrease organically. The GAAP diluted EPS was $0.94, while the non-GAAP diluted EPS was $1.29, both decreasing by 10%. The company's performance was impacted by the resurgence of COVID-19, which affected procedure volumes.

Medtronic reported a decrease in revenue by 0.8% to $7.6 billion. The GAAP diluted EPS was $0.36, and the non-GAAP diluted EPS was $1.02.

Medtronic reported a 13% decrease in Q1 revenue to $6.507 billion, with a GAAP diluted EPS of $0.36 and a non-GAAP diluted EPS of $0.62. The results were impacted by the COVID-19 pandemic, but the company saw a faster than expected recovery with improving procedure volumes.

Medtronic reported a 26% decrease in Q4 revenue to $6.0 billion, with GAAP EPS at $0.48 and non-GAAP EPS at $0.58. The results were in line with previous updates, reflecting the impact of deferred procedures due to the COVID-19 pandemic. Despite the challenges, the company increased its dividend, showcasing its financial strength.

Medtronic reported a 2.3% increase in revenue to $7.7 billion and a 51% increase in GAAP diluted EPS to $1.42. The company also raised its full-year EPS guidance.